Amgen Inc

“Amgen generates exceptional cash flows from a durable biologics franchise, but the $28B Horizon acquisition has left it with $54.6B in gross debt, negative tangible book value, and a tight FCF-to-dividend ratio — while its two largest legacy products face accelerating biosimilar erosion and the transformative MariTide obesity program remains unproven in Phase 3. At 13.7x forward earnings with a ~7% base-case total return and limited margin of safety, the stock fairly prices the business as-is; meaningful upside requires MariTide success against entrenched GLP-1 incumbents. Track for a better entry at 10-11x forward earnings or for Phase 3 MariTide data resolution.”